Info

Genome integration

No

Site-specific

Random

No

No

Immunoreactive

Yes/no

No

No

Yes

No

"This table lists the key attributes of the vectors used previously in gene therapy clinical trials for prostate cancer.

"This table lists the key attributes of the vectors used previously in gene therapy clinical trials for prostate cancer.

ment of vector systems for the delivery of those genes. Prostate-specific targeting of molecular therapies is now possible because of the identification and characterization of prostate-specific sequences. Our laboratory has focused much of its efforts on the development of chimeric tissue-specific promoters, such as prostate-specific enhancing sequence (PSES), and the application of well-characterized promoters, such as osteocalcin (OC), in the development of molecular therapy for androgen-independent primary and metastatic prostate cancer, which has translated to several clinical trials. In this chapter, we review the current status of gene therapy for advanced prostate cancer.

Was this article helpful?

0 0

Post a comment